These include immunotherapy with immune checkpoint inhibitors for high-microsatellite-instability cancers, combinations of anti-EGFR antibodies with BRAF inhibitors for patients with BRAF mutations, combinations of anti-EGFR antibodies with KRAS inhibitors for patients with C12S KRAS mutations, and targeted HER2 therapies for patients with colorectal cancers bearing ERBB2 amplifications or overexpression [6,7,8,13]. This evidence concerns the gene ERBB2 and colorectal cancer.